The SAR analysis of TRPV1 agonists with the α-methylated B-region
Graphical abstract
Section snippets
Acknowledgments
This research was supported by Grants R11-2007-107-02001-0 from the NRF and was supported in part by the Intramural Research Program of the National Institutes of Health, Center for Cancer Research, National Cancer Institute (Project Z1A BC 005270). We thank other members of the Blumberg group for assistance with some of the assays.
References and notes (22)
- et al.
Eur. J. Pharmacol.
(2004) - et al.
Pharmacol. Ther.
(2010) - et al.
Neuron
(1998) - et al.
Life Sci.
(1997) - et al.
Drug Discovery Today
(2009) - et al.
Brain Res. Rev.
(2009) - et al.
Bioorg. Med. Chem.
(2012) - et al.
Bioorg. Med. Chem. Lett.
(2005) - et al.
Bioorg. Med. Chem. Lett.
(2004) - et al.
Bioorg. Med. Chem.
(2010)
Bioorg. Med. Chem.
(2002)
Cited by (5)
Short-chain phosphoinositide partitioning into plasma membrane models
2013, Biophysical JournalCitation Excerpt :Fatty acids of different length and saturation have varying effects on TRPV1 (49). Future structure-activity relationship studies involving amphiphilic compounds (for instance, recent SAR studies of TRPV1 antagonists (50,51)) should probably explicitly account for the membrane partition of each compound in determining specificity and mechanism. Our results are limited to the lipid mixtures we have used.
A new era for the design of TRPV1 antagonists and agonists with the use of structural information and molecular docking of capsaicin-like compounds
2022, Journal of Enzyme Inhibition and Medicinal ChemistryUnderstanding TRPV1 activation by ligands: Insights from the binding modes of capsaicin and resiniferatoxin
2016, Proceedings of the National Academy of Sciences of the United States of America
Copyright © 2012 Elsevier Ltd. All rights reserved.